Eli Lilly’s Mounjaro has become India’s highest-selling pharmaceutical brand, with annual sales hitting ₹1,256 crore. This growth signals a major shift in the Indian healthcare market as patients move from oral pills to injectable GLP-1 treatments for diabetes and weight management.
Eli Lilly’s Mounjaro, a treatment for diabetes and obesity, has ascended to become India’s top-selling pharmaceutical brand. Data for the 12-month period ending August 2026 shows the drug reached annual sales of ₹1,256 crore, a 502% increase over the previous year. This rapid growth allowed it to surpass long-standing market leaders like Augmentin and Glycomet, marking a turning point in the domestic pharmaceutical landscape.
The surge in sales reflects a structural change in how patients manage chronic conditions. The total market for GLP-1 treatments in India has expanded to ₹2,333 crore, with tirzepatide—the active ingredient in Mounjaro—now accounting for 62% of this value. Healthcare professionals note that patients are increasingly preferring once-weekly injectable treatments over daily oral medications, citing better convenience and efficacy in appetite control and metabolic regulation.
Global Growth and Regulatory Milestones
Eli Lilly’s success in India mirrors its strong global performance. In the second quarter of 2026, the company reported global revenue of $23.0 billion, a 48% increase compared to the same period last year. Following this performance, the company raised its full-year 2026 revenue guidance to a range of $85.0 billion to $87.0 billion. In August 2026, the company also received US FDA approval to market Mounjaro for the reduction of major adverse cardiovascular events in adults with type 2 diabetes, further expanding the drug’s medical utility.
Investor Monitorables and Risks
While the commercial growth is significant, investors often monitor several factors that could influence future performance. Eli Lilly’s stock, trading around the $1,150–$1,160 range in early September 2026, has seen recent volatility and is currently trading below its 52-week high of $1,292.65.
Beyond the immediate success in India, the long-term outlook depends on several variables. The pharmaceutical sector faces potential pressure from generic competition as patents eventually expire and new, alternative therapies enter the market. Additionally, the company faces global risks related to pricing and reimbursement policies, which can affect profit margins. Investors also track the company's aggressive business development activities, as significant investments in research and development and potential acquisitions can sometimes impact short-term earnings. Moving forward, market participants will watch for updates on pricing stability, new competitive entries in the GLP-1 segment, and the company's ability to maintain high demand across diverse global markets.